Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Recruiting
18 years - 99 years
All
Phase 2
62 participants needed
1 Location

Brief description of study

The purpose of this study is to see if the Study drug works in the prevention of cytokine release syndrome. This is an open-label study, which means that both the participant and the study Doctor will know what study drug the participant is receiving. Participants will be in the study for about 8 months. This includes 1 month on treatment, followed by a 1 month, 3 month, and a 6 month follow-up visit.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: cytokine release syndrome
  • Age: 18 years - 99 years
  • Gender: All
Updated on 04 Aug 2024. Study ID: 842752

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center